Evidence map›Paper›PMID 38913956›Full record

ArticleDiabetes care2024

Lifetime Medical Spending Attributed to Incident Type 2 Diabetes in Medicare Beneficiaries: A Longitudinal Study Using 1999-2019 National Medicare Claims.

Yixue Shao, Yu Wang, Elizabeth Bigman, Giuseppina Imperatore, Christopher Holliday, Ping Zhang

Abstract read
In one paragraph

Article in Diabetes care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Zero Dollar Copay Pharmacy Benefit Decreases Healthcare Expenditures Among Members With Type 2 Diabetes of Blue Cross Blue Shield of Louisiana.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yixue ShaoDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.ORCID 0000-0003-1410-5455
Yu WangDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.ORCID 0000-0003-4740-6406
Elizabeth BigmanDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.
Giuseppina ImperatoreDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.
Christopher HollidayDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.
Ping ZhangDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.ORCID 0000-0001-8429-6301

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

objectiveTo estimate lifetime incremental medical spending attributed to incident type 2 diabetes (T2D) among Medicare beneficiaries by age at diagnosis, sex, and race/ethnicity. RESEARCH DESIGN AND

methodsWe used the 1999-2019 100% Medicare fee-for-service claims database to identify a cohort of beneficiaries with newly diagnosed T2D in 2001-2003 using ICD codes. We matched this cohort with a nondiabetes cohort using a propensity score method and then followed the two cohorts until death, disenrollment, or the end of 2019. Lifetime medical spending for each cohort was the sum of expected annual spending, a product of actual annual spending multiplied by the annual survival rate, from the age at T2D diagnosis to death. Lifetime incremental medical spending was calculated as the difference in lifetime medical spending between the two cohorts. All spending was standardized to 2019 U.S. dollars.

resultsMedicare beneficiaries with newly diagnosed T2D, despite having a shorter life expectancy, had 36-40% higher lifetime medical spending compared with a comparable group without diabetes. Lifetime incremental medical spending ranged from $16,115 to $122,146, depending on age at diagnosis, sex, and race/ethnicity, declining with age at diagnosis, and being highest for Asian/Pacific Islander and non-Hispanic Black beneficiaries.

conclusionsThe large lifetime incremental medical spending associated with incident T2D underscores the need for preventing T2D among Medicare beneficiaries. Our results could be used to estimate the potential financial benefit of T2D prevention programs both overall and among subgroups of beneficiaries.

Indexed as

Diabetes Mellitus, Type 2Health ExpendituresMedicareAgedAged, 80 and overFemaleHumansLongitudinal StudiesMaleUnited States

Identifiers

PMID38913956
PMCPMC11342786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.